|
|
|
14.07.25 - 12:03
|
Exact Sciences Schedules Second Quarter 2025 Earnings Call (Business Wire)
|
|
|
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2025 financial results after the close of the U.S. financial markets on August 6, 2025. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress.
Second quarter 2025 webcast & conference call details
Date:
Wednesday, August 6, 2025
Time:
5 p.m. ET
Webcast:
The live webcast can be accessed at www.exactsciences.com
Telephone:
Domestic callers, dial 888-330-2384
International callers, dial +1 240-789-2701
Access code for both domestic and international callers: 4437608
A replay of the webcast will be available at www.exactsciences.com. The webcast, conference call, and replay are open to all interested parties.
About Exact Sciences Corp.
A leading provider of cancer screening and diagnostic tests, Exact Sciences helps patient...
|
|
|
|
|
|
|
25.06.25 - 21:48
|
Could Personalized Medicine Be Your Portfolios Next Big Winner? Find Out (Benzinga)
|
|
|
BofA analysts review the promise and limits of AI in precision medicine, highlighting key players like Tempus, Guardant, and Exact Sciences.
Latest Ratings for EXAS
DateFirmActionFromTo Feb 2022Wells FargoMaintainsEqual-Weight Feb 2022CitigroupMaintainsNeutral Feb 2022Raymond JamesMaintainsOutperform
View More Analyst Ratings for EXAS
View the Latest Analyst Ratings
read more...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
01.05.25 - 22:06
|
Exact Sciences Announces First-Quarter 2025 Results (Business Wire)
|
|
|
First quarter highlights
Delivered total first quarter revenue of $707 million, an increase of 11% on a reported and core revenue basis, including Screening revenue of $540 million and Precision Oncology revenue of $167 million
Raised full-year 2025 revenue and adjusted EBITDA guidance midpoints by $40 million and $15 million, respectively
Launched the Cologuard Plus™ test, the company's next-generation colon cancer screening test
Presented data in the Journal of Surgical Oncology demonstrating the clinical strength of the Oncodetect™ test, the company's molecular residual disease (“MRD”) and recurrence monitoring test
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $707 million for the first quarter ended March 31, 2025, compared to $638 million for the same period of 2024.
“Our strong first quarter results pave the way for 2025 to mark our most transformativ...
|
|
|
|
|
01.04.25 - 12:03
|
Exact Sciences Schedules First Quarter 2025 Earnings Call (Business Wire)
|
|
|
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 2025 financial results after the close of the U.S. financial markets on May 1, 2025. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress.
First quarter 2025 webcast & conference call details
Date:
Thursday, May 1, 2025
Time:
5 p.m. ET
Webcast:
The live webcast can be accessed at www.exactsciences.com
Telephone:
Domestic callers, dial 888-330-2384
International callers, dial +1 240-789-2701
Access code for both domestic and international callers: 4437608
A replay of the webcast will be available at www.exactsciences.com. The webcast, conference call, and replay are open to all interested parties.
About Exact Sciences Corp.
A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and hea...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
